Showing results (261-270 of 427) with videos related to

Sort By:
Pageof 43
Mediterranean Journal of Hematology and Infectious Diseases|June 18, 2019
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian PopulationElisabetta Abruzzese, Alberto Bosi, Massimo Breccia, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Annals of Hematology|March 21, 2014
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective studyCaterina Tatarelli, Anna Lina Piccioni, Luca Maurillo, et al.
European Journal of Haematology|March 13, 2015
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro BasilicataLuca Maurillo, Massimo Breccia, Francesco Buccisano, et al.
Experimental Hematology|July 3, 2026
Multidisciplinary Characterization of Rare MPL Y591 and R592 Variants in Myeloid Disorders: From Clinical Correlation and Literature-Based Evidence to In Silico Predictors and Structural BioinformaticsAlessandro Laganà, Giovanni Iaquinta, Michelina Santopietro, et al.
Hematological Oncology|May 17, 2017
Comparison of JAK2<sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histologyRoberto Latagliata, Nicola Polverelli, Alessia Tieghi, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Hematological Oncology|August 8, 2025
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE StudyAlessandra Iurlo, Massimo Breccia, Fabio Stagno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Leukemia Research|December 23, 2018
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?Ambra Di Veroli, Alessia Campagna, Marianna De Muro, et al.
Pageof 43